Ralph H Hruban

List of Publications by Year in Descending Order

668 papers	87,155 citations	137 h-index	289 g-index
700 ext. papers	100,844 ext. citations	9.4 avg, IF	7.41 L-index

#	Paper	IF	Citations
668	Accurate Nodal Staging in Pancreatic Cancer in the Era of Neoadjuvant Therapy.. *World Journal of Surgery*, **2022**,	3.3	1
667	Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity.. *Annals of Surgical Oncology*, **2022**, 29, 2456	3.1	1
666	Pathology of Pancreatic Cancer **2022**, 91-97		
665	Endoplasmic stress-inducing variants in CPB1 and CPA1 and risk of pancreatic cancer: A case-control study and meta-analysis. *International Journal of Cancer*, **2021**, 150, 1123	7.5	0
664	A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. *British Journal of Cancer*, **2021**, 125, 1712-1717	8.7	1
663	Minimal main pancreatic duct dilatation in small branch duct intraductal papillary mucinous neoplasms associated with high-grade dysplasia or invasive carcinoma. *Hpb*, **2021**, 23, 468-474	3.8	1
662	Multiscale label-free volumetric holographic histopathology of thick-tissue slides with subcellular resolution. *Advanced Photonics*, **2021**, 3,	8.1	12
661	Guidelines on management of pancreatic cysts detected in high-risk individuals: An evaluation of the 2017 Fukuoka guidelines and the 2020 International Cancer of the Pancreas Screening (CAPS) consortium statements. *Pancreatology*, **2021**, 21, 613-621	3.8	4
660	Pathology of intraductal papillary mucinous neoplasms. *Langenbeck's Archives of Surgery*, **2021**, 1	3.4	1
659	Current Status of Radiomics and Deep Learning in Liver Imaging. *Journal of Computer Assisted Tomography*, **2021**, 45, 343-351	2.2	0
658	Downregulation of 5-hydroxymethylcytosine is an early event in pancreatic tumorigenesis. *Journal of Pathology*, **2021**, 254, 279-288	9.4	2
657	A Department-Sponsored, Hospital-Based Pathology Education Symposium Is a Cost-Effective Method to Provide Laboratory Staff With Highly Rated Continuing Education Experiences. *Archives of Pathology and Laboratory Medicine*, **2021**, 145, 231-239	5	0
656	Defining a minimum number of examined lymph nodes improves the prognostic value of lymphadenectomy in pancreas ductal adenocarcinoma. *Hpb*, **2021**, 23, 575-586	3.8	4
655	Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. *Modern Pathology*, **2021**, 34, 4-12	9.8	12
654	Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. *Cancer Letters*, **2021**, 497, 221-228	9.9	7
653	Pancreatic Cancer Imaging: A New Look at an Old Problem. *Current Problems in Diagnostic Radiology* , **2021**, 50, 540-550	1.6	8
652	Long-term outcomes with neoadjuvant chemotherapy with or without stereotactic body radiation therapy in patients with borderline resectable and locally advanced pancreatic adenocarcinoma.. *Journal of Clinical Oncology*, **2021**, 39, 443-443	2.2	0

651	Pancreatic cancer pathology viewed in the light of evolution. *Cancer and Metastasis Reviews*, **2021**, 40, 661-674	9.6	3
650	Ovarian Metastasis from Pancreatic Ductal Adenocarcinoma. *World Journal of Surgery*, **2021**, 45, 3157-3164	3.3	0
649	Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. *Pancreatology*, **2021**, 21, 938-941	3.8	0
648	Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. *Annals of Surgical Oncology*, **2021**, 1	3.1	3
647	Proteogenomic characterization of pancreatic ductal adenocarcinoma. *Cell*, **2021**, 184, 5031-5052.e26	56.2	26
646	ASO Visual Abstract: Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. *Annals of Surgical Oncology*, **2021**, 28, 714-715	3.1	1
645	Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. *JAMA Oncology*, **2021**, 7, 1664-1668	13.4	7
644	CT Radiomics-Based Preoperative Survival Prediction in Patients With Pancreatic Ductal Adenocarcinoma. *American Journal of Roentgenology*, **2021**, 217, 1104-1112	5.4	1
643	Pathology Residency Program Special Expertise Tracks Meet the Needs of an Evolving Field. *Academic Pathology*, **2021**, 8, 23742895211037034	1.3	0
642	Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System. *Cancer Discovery*, **2021**,	24.4	5
641	Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Society. *American Journal of Surgical Pathology*, **2021**,	6.7	1
640	Gastric cancer following pancreaticoduodenectomy: Experience from a high-volume center and review of existing literature. *Surgery Open Science*, **2020**, 2, 32-40	1.2	0
639	Diagnostic performance of commercially available vs. in-house radiomics software in classification of CT images from patients with pancreatic ductal adenocarcinoma vs. healthy controls. *Abdominal Radiology*, **2020**, 45, 2469-2475	3	8
638	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. *Cell Reports*, **2020**, 31, 107625	10.6	34
637	Three-dimensional analysis of extrahepatic cholangiocarcinoma and tumor budding. *Journal of Pathology*, **2020**, 251, 400-410	9.4	4
636	Acinar cell carcinoma of the pancreas: a clinicopathologic and cytomorphologic review. *Journal of the American Society of Cytopathology*, **2020**, 9, 586-595	2.4	5
635	Intraductal pancreatic cancer is less responsive than cancer in the stroma to neoadjuvant chemotherapy. *Modern Pathology*, **2020**, 33, 2026-2034	9.8	3
634	The Evolutionary Origins of Recurrent Pancreatic Cancer. *Cancer Discovery*, **2020**, 10, 792-805	24.4	33

633	Assessing aneuploidy with repetitive element sequencing. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 4858-4863	11.5	26
632	Invasive Intraductal Papillary Mucinous Neoplasms: CT Features of Colloid Carcinoma Versus Tubular Adenocarcinoma of the Pancreas. *American Journal of Roentgenology*, **2020**, 214, 1092-1100	5.4	4
631	Primary pancreatic Ewing sarcoma: a cytomorphologic and histopathologic study of 13 cases. *Journal of the American Society of Cytopathology*, **2020**, 9, 502-512	2.4	2
630	Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours. *Pathology*, **2020**, 52, 336-347	1.6	7
629	Cell fitness screens reveal a conflict between LINE-1 retrotransposition and DNA replication. *Nature Structural and Molecular Biology*, **2020**, 27, 168-178	17.6	31
628	Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. *Journal of the National Cancer Institute*, **2020**, 112, 1162-1169	9.7	48
627	Generation and characterization of a cell line from an intraductal tubulopapillary neoplasm of the pancreas. *Laboratory Investigation*, **2020**, 100, 1003-1013	5.9	3
626	Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. *Science*, **2020**, 369,	33.3	149
625	Guidelines on the histopathology of chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and the European Pancreatic Club. *Pancreatology*, **2020**, 20, 586-593	3.8	22
624	Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. *Journal of Molecular Diagnostics*, **2020**, 22, 748-756	5.1	4
623	Desmin and CD31 immunolabeling for detecting venous invasion of the pancreatobiliary tract cancers. *PLoS ONE*, **2020**, 15, e0242571	3.7	2
622	Invasive and Non-Invasive Progression after Resection of Non-Invasive Intraductal Papillary Mucinous Neoplasms. *Annals of Surgery*, **2020**,	7.8	4
621	Three-dimensional visualization of cleared human pancreas cancer reveals that sustained epithelial-to-mesenchymal transition is not required for venous invasion. *Modern Pathology*, **2020**, 33, 639-647	9.8	21
620	Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 1161-1169.e5	6.9	10
619	Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct. *Gastroenterology*, **2020**, 158, 573-582.e2	13.3	56
618	Multiple Carcinomas and Intraepithelial Neoplasms in a Case of Familial Pancreatic Cancer: Rapid Morphological Changes in the Pancreatic Cyst and Pathological Lesions Undetected by Clinical Images. *Internal Medicine*, **2020**, 59, 1041-1046	1.1	
617	A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma.. *Nature Cancer*, **2020**, 1, 59-74	15.4	56
616	Revisiting the tumorigenesis timeline with a data-driven generative model. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 857-864	11.5	26

615	Pitfalls in the MDCT of pancreatic cancer: strategies for minimizing errors. *Abdominal Radiology*, **2020**, 45, 457-478	3	4
614	Pancreatic volume does not correlate with histologic fibrosis in adult patients with recurrent acute and chronic pancreatitis. *Pancreatology*, **2020**, 20, 1078-1084	3.8	2
613	Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms. *Journal of Pathology*, **2020**, 252, 252-262	9.4	18
612	Medullary Pancreatic Carcinoma Due to Somatic POLE Mutation: A Distinctive Pancreatic Carcinoma With Marked Long-Term Survival. *Pancreas*, **2020**, 49, 999-1003	2.6	12
611	The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. *Modern Pathology*, **2020**, 33, 2544-2563	9.8	9
610	Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. *Cancer Discovery*, **2020**, 10, 1566-1589	24.4	39
609	Comprehensive histological evaluation with clinical analysis of venous invasion in pancreatic ductal adenocarcinoma: From histology to clinical implications. *Pancreatology*, **2020**, 20, 1486-1494	3.8	1
608	Genomic characterization of malignant progression in neoplastic pancreatic cysts. *Nature Communications*, **2020**, 11, 4085	17.4	27
607	Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. *Journal of Gastrointestinal Surgery*, **2020**, 24, 1101-1110	3.3	26
606	Pancreatic Nerve Sheath Tumors: a Single Institutional Series and Systematic Review of the Literature. *Journal of Gastrointestinal Surgery*, **2020**, 24, 841-848	3.3	3
605	Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. *Annals of Surgery*, **2020**, 271, 566-573	7.8	42
604	A semicentennial of pancreatic pathology: the genetic revolution is here, but don't throw the baby out with the bath water!. *Human Pathology*, **2020**, 95, 99-112	3.7	1
603	Intraductal Papillary Mucinous Neoplasms Arise From Multiple Independent Clones, Each With Distinct Mutations. *Gastroenterology*, **2019**, 157, 1123-1137.e22	13.3	40
602	Multiple KRAS mutations in the non-mucinous epithelial lining in the majority of mucinous cystic neoplasms of the pancreas. *Histopathology*, **2019**, 75, 559-567	7.3	4
601	The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. *Science*, **2019**, 364, 1156-1162	33.3	92
600	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. *Clinical Cancer Research*, **2019**, 25, 4973-4984	12.9	55
599	Utility of CT Radiomics Features in Differentiation of Pancreatic Ductal Adenocarcinoma From Normal Pancreatic Tissue. *American Journal of Roentgenology*, **2019**, 213, 349-357	5.4	62
598	Why is pancreatic cancer so deadly? The pathologist's view. *Journal of Pathology*, **2019**, 248, 131-141	9.4	39

597	Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms. *Gastroenterology*, **2019**, 156, 1905-1913	13.3	27
596	Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. *Clinical Epigenetics*, **2019**, 11, 59	7.7	65
595	Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance. *Journal of Clinical Oncology*, **2019**, 37, 1070-1080	2.2	36
594	Screening for Pancreatic Cancer-Is There Hope?. *JAMA Internal Medicine*, **2019**, 179, 1313-1315	11.5	6
593	Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants. *Modern Pathology*, **2019**, 32, 1806-1813	9.8	11
592	A multimodality test to guide the management of patients with a pancreatic cyst. *Science Translational Medicine*, **2019**, 11,	17.5	71
591	Follow-up of Incidentally Detected Pancreatic Cystic Neoplasms: Do Baseline MRI and CT Features Predict Cyst Growth?. *Radiology*, **2019**, 292, 647-654	20.5	13
590	Application of Deep Learning to Pancreatic Cancer Detection: Lessons Learned From Our Initial Experience. *Journal of the American College of Radiology*, **2019**, 16, 1338-1342	3.5	37
589	The "Race" Toward Diversity, Inclusion, and Equity in Pathology: The Johns Hopkins Experience. *Academic Pathology*, **2019**, 6, 2374289519873104	1.3	10
588	Biphenotypic Differentiation of Pancreatic Cancer in 3-Dimensional Culture. *Pancreas*, **2019**, 48, 1225-1236	3.6	2
587	Well-differentiated Pancreatic Neuroendocrine Tumor in a Patient With Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM). *American Journal of Surgical Pathology*, **2019**, 43, 1297-1302	6.7	1
586	Genomic Applications in Pancreatic and Gastric Tumors **2019**, 401-418		
585	Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. *Modern Pathology*, **2019**, 32, 659-665	9.8	14
584	Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions. *Journal of Pathology*, **2019**, 247, 347-356	9.4	27
583	A "Clearer" View of Pancreatic Pathology: A Review of Tissue Clearing and Advanced Microscopy Techniques. *Advances in Anatomic Pathology*, **2019**, 26, 31-39	5.1	13
582	Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. *Annals of Surgery*, **2019**, 270, 340-347	7.8	149
581	IPMNs with co-occurring invasive cancers: neighbours but not always relatives. *Gut*, **2018**, 67, 1652-1662	19.2	58
580	Immunolabeling of Cleared Human Pancreata Provides Insights into Three-Dimensional Pancreatic Anatomy and Pathology. *American Journal of Pathology*, **2018**, 188, 1530-1535	5.8	22

579	Mutations in the pancreatic secretory enzymes and are associated with pancreatic cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 4767-4772	11.5	34
578	Detection of aneuploidy in patients with cancer through amplification of long interspersed nucleotide elements (LINEs). *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 1871-1876	11.5	30
577	Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?. *Annals of Surgery*, **2018**, 268, 1-8	7.8	98
576	Detection and localization of surgically resectable cancers with a multi-analyte blood test. *Science*, **2018**, 359, 926-930	33.3	1204
575	Development of the Pancreas and Related Structures **2018**, 1-9		
574	Fibrogenesis in the Pancreas **2018**, 106-116		
573	Tumor Markers in Pancreatic Malignancies **2018**, 762-765		
572	The Role of Laparoscopy and Peritoneal Cytology in the Management of Pancreatic Cancer **2018**, 766-769		
571	Clinical Assessment and Staging of Advanced Pancreatic Cancer **2018**, 770-775		
570	Pancreaticoduodenectomy for Pancreatic Cancer, Short- and Long-Term Outcomes After Kausch Whipple and Pylorus-Preserving Resection **2018**, 783-789		
569	Left Pancreatectomy for Body and Tail Cancer **2018**, 790-796		
568	Total Pancreatectomy **2018**, 797-803		
567	Laparoscopic and Robotic Resection for Pancreatic Cancer **2018**, 804-813		
566	Extended Radical Surgery for Pancreatic Cancer **2018**, 814-822		
565	Palliative Pancreatoduodenectomy **2018**, 823-827		
564	Fibrogenesis of the Pancreas **2018**, 117-122		
563	Bypass Surgery for Advanced Pancreatic Cancer **2018**, 828-834		
562	Endoscopic and Interventional Palliation of Pancreatic Cancer **2018**, 835-841		

561 Neoadjuvant Treatment of Pancreatic Cancer **2018**, 842-846

560 Adjuvant Chemotherapy in Pancreatic Cancer **2018**, 847-855 1

559 Immunotherapy for Pancreatic Cancer **2018**, 856-864

558 Targeted Therapies for Pancreatic Cancer **2018**, 865-871

557 Palliative Chemotherapy for Advanced Pancreatic Cancer **2018**, 872-878

556 Management of Pain in Pancreatic Cancer **2018**, 879-885

555 Role of Radio and Proton Beam Therapy for Pancreatic Cancer **2018**, 886-894

554 Management of Cancer Recurrence **2018**, 895-905 1

553 InsuloAcinar Relationship **2018**, 123-131

552 Survival and Late Morbidity After Resection of Pancreatic Cancer **2018**, 906-917

551 Epidemiology and Classification of Neuroendocrine Tumors of the Pancreas **2018**, 919-929

550 Pathology of Neuroendocrine Neoplasms **2018**, 930-936

549 Clinical Manifestation of Endocrine Tumors of the Pancreas **2018**, 947-952

548 Evidence of Hormonal, Laboratory, Biochemical, and Instrumental Diagnostics of Neuroendocrine Tumors of the Pancreas **2018**, 953-960

547 Pancreatic Neuroendocrine Tumors in Multiple Neoplasia Syndromes **2018**, 961-966

546 Nonfunctioning Pancreatic Neuroendocrine Tumors **2018**, 967-971

545 Medical and Nucleotide Treatment of Neuroendocrine Tumors of the Pancreas **2018**, 972-978

544 Interventional Radiology in the Treatment of Pancreatic Neuroendocrine Tumors **2018**, 979-981

543 Epidemiology and Etiology of Alcohol-Induced Pancreatitis **2018**, 133-145

542 Surgical Treatment of Endocrine Tumors **2018**, 982-988

541 Local Treatment of Endocrine Tumors **2018**, 989-993

540 Surgical Treatment of Endocrine Tumors **2018**, 994-1001

539 Management of Insulinoma **2018**, 1002-1008

538 Evidence of Medical and Surgical Treatment of Gastrinoma **2018**, 1009-1012

537 Rare Neuroendocrine Tumors of the Pancreas **2018**, 1013-1018

536 Treatment of Neuroendocrine Tumors of the Pancreas and Biliary Tract **2018**, 1019-1028

535 Long-Term Outcome After Treatment of Endocrine Tumors **2018**, 1029-1034

534 Periampullary Cancer **2018**, 1035-1046

533 Histology and Genetics of Cancer of the Papilla, Distal Common Bile Duct, and Duodenum **2018**, 1047-1057

532 Epidemiology and Etiology of Acute Biliary Pancreatitis **2018**, 146-157 2

531 Adenoma and Adenocarcinoma of the Ampulla of Vater **2018**, 1058-1067

530 Endoscopic Treatment of Adenomas of the Ampulla of Vater **2018**, 1068-1073

529 Surgical Treatment of Adenoma and Cancer of Papilla of Vater **2018**, 1074-1080

528 Surgical Treatment of Duodenal Cancer **2018**, 1081-1082

527 Surgical Treatment of Distal Cholangiocarcinoma **2018**, 1083-1088

526 Adjuvant and Palliative Chemotherapy of Periampullary Cancers **2018**, 1089-1096

525 Long-Term Survival After Resection of Periampullary Cancer **2018**, 1097-1106 2

524 Transplantation of Pancreatic Islets **2018**, 1107-1120

523 Transplantation of the Pancreas **2018**, 1121-1128

522 Genetic Factors in Acute Pancreatitis **2018**, 158-165

521 The Role of the Intestine and Mesenteric Lymph in the Development of Systemic Inflammation and MODS in Severe Acute Pancreatitis **2018**, 166-172

520 The Role of Neurogenic Inflammation in Pancreatitis **2018**, 173-177

519 Molecular, Biochemical, and Metabolic Abnormalities in Acute Pancreatitis **2018**, 178-192

518 Histopathology of Acute Pancreatitis **2018**, 193-198 0

517 Anatomy, Histology, and Fine Structure of the Pancreas **2018**, 10-23 3

516 Clinical Classification Systems of Acute Pancreatitis **2018**, 199-203

515 Clinical Assessment and Biochemical Markers to Objectify Severity and Prognosis **2018**, 204-212 1

514 Acute Pancreatitis Associated With Congenital Anomalies **2018**, 213-218

513 Acute Pancreatitis in Children **2018**, 219-229

512 Acute Pancreatitis Associated With Metabolic Disorders, Infectious Diseases, or Drugs **2018**, 230-237

511 Radiologic Diagnosis and Staging of Severe Acute Pancreatitis **2018**, 238-250

510 Conservative Therapy of Acute Pancreatitis **2018**, 251-257

509 ICU Treatment of Severe Acute Pancreatitis **2018**, 258-264

508 Use of Antibiotics in Severe Acute Pancreatitis **2018**, 265-270

507 Indications for Interventional and Surgical Treatment of Necrotizing Pancreatitis **2018**, 271-276

506 Congenital and Inherited Anomalies of the Pancreas **2018**, 24-39

505 Management of Infected Pancreatic Necroses **2018**, 277-282

504 Minimally Invasive Debridement and Lavage of Necrotizing Pancreatitis **2018**, 283-288

503 Open Surgical Debridement in Necrotizing Pancreatitis **2018**, 289-295

502 Endoscopic Treatment of Biliary Acute Pancreatitis **2018**, 296-300

501 Strategies for the Treatment of Pancreatic Pseudocysts and Walled-Off Necrosis After Acute Pancreatitis **2018**, 301-304

500 Strategies for the Treatment of Pancreatic Pseudocysts and Walled-Off Necrosis After Acute Pancreatitis **2018**, 305-310

499 Management of Fluid Collection in Acute Pancreatitis **2018**, 311-315

498 Management of Pancreatic Fistula in Acute Pancreatitis **2018**, 316-322

497 Long-Term Outcome After Acute Pancreatitis **2018**, 323-330

496 Molecular Understanding of Chronic Pancreatitis **2018**, 331-341

495 Physiology of Acinar Cell Secretion **2018**, 41-55 1

494 Epidemiology and Pathophysiology of Alcoholic Chronic Pancreatitis **2018**, 342-348

493 Pain Mechanisms in Chronic Pancreatitis **2018**, 349-354

492 Natural History of Recurrent Acute and Chronic Pancreatitis **2018**, 355-364

491 Chronic Pancreatitis with Inflammatory Mass of the Pancreatic Head **2018**, 365-370

490 Early Chronic Pancreatitis **2018**, 371-373

471 Epidemiology of Autoimmune Pancreatitis **2018**, 503-509 1

470 Pathogenesis of Autoimmune Pancreatitis **2018**, 510-515

469 Histology of Autoimmune Pancreatitis **2018**, 516-519 1

468 Clinical Manifestation of Type 1 Autoimmune Pancreatitis **2018**, 520-533

467 Clinical Manifestations of Type 2 Autoimmune Pancreatitis **2018**, 534-538

466 Laboratory Diagnosis of Autoimmune Pancreatitis **2018**, 539-543

465 What is the Evidence Measuring Immune Markers **2018**, 544-549

464 Physiology and Pathophysiology of Function of Sphincter of Oddi **2018**, 75-83

463 Imaging Diagnosis of Autoimmune Pancreatitis **2018**, 550-554

462 Medical Management of Autoimmune Pancreatitis **2018**, 555-559

461 Long-Term Outcome After Treatment of Autoimmune Pancreatitis **2018**, 560-564

460 Epidemiology of Cystic Neoplasms of the Pancreas **2018**, 565-572 1

459 Histologic Classification and Staging of Cystic Neoplasms **2018**, 573-579

458 Clinical Presentation of Cystic Neoplasms **2018**, 589-592

457 Evaluation of Cystic Lesions Using EUS, MRI, and CT **2018**, 593-602

456 Cytologic Evaluation of Cystic Neoplasms **2018**, 603-610

455 Natural History of Cystic Neoplasms **2018**, 611-617

454 Neurohormonal and Hormonal Control of Pancreatic Secretion **2018**, 84-94 1

453 Surveillance or Surgical Treatment in Asymptomatic Cystic Neoplasms **2018**, 618-621

452 Duodenum-Preserving Partial or Total Pancreatic Head Resection **2018**, 622-626

451 Pancreatic Middle Segment Resection **2018**, 627-631

450 The Indications For and Limitations of Tumor Enucleation **2018**, 632-640

449 Standard Surgical Management of IPMN, MCN, SPN, and SCN Lesions **2018**, 641-648

448 Surgical Treatment of Cystic Neoplasms **2018**, 649-654

447 Management of Recurrence of Cystic Neoplasms **2018**, 655-659

446 Long-Term Outcome After Observation and Surgical Treatment **2018**, 660-664

445 Epidemiology of Pancreatic Cancer **2018**, 665-672

444 Smoking, a Risk for Pancreatic Cancer **2018**, 673-678

443 Regulation of Pancreatic Protein Synthesis and Growth **2018**, 95-105

442 Familial Pancreatic Cancer **2018**, 688-692

441 Clinical History and Risk Factors of Pancreatic Cancer **2018**, 717-723

440 Pancreatic Cancer Within the Uncinate Process **2018**, 724-727 1

439 The Role of EUS in the Diagnosis and Differential Diagnosis of Neoplastic Lesions **2018**, 728-732 1

438 Radiologic Diagnosis of Pancreatic Cancer **2018**, 733-744

437 Screening of Patients with Hereditary Pancreatic Cancer **2018**, 745-754

436 The Role of PET in Diagnosis of Pancreatic Cancer and Cancer Recurrence **2018**, 755-761

435	Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. *Pancreas*, **2018**, 47, 208-212	2.6	14
434	Genome-Wide Somatic Copy Number Alterations and Mutations in High-Grade Pancreatic Intraepithelial Neoplasia. *American Journal of Pathology*, **2018**, 188, 1723-1733	5.8	21
433	Lessons learned from 29 lymphoepithelial cysts of the pancreas: institutional experience and review of the literature. *Hpb*, **2018**, 20, 612-620	3.8	8
432	Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy. *Surgery*, **2018**, 163, 1090-1096	3.6	22
431	Pancreatic neuroendocrine tumor: review of heterogeneous spectrum of CT appearance. *Abdominal Radiology*, **2018**, 43, 3025-3034	3	12
430	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. *Science Translational Medicine*, **2018**, 10,	17.5	110
429	Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium. *Annals of Surgery*, **2018**, 267, 157-163	7.8	66
428	Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. *Annals of Surgery*, **2018**, 268, 340-347	7.8	26
427	Intraductal Papillary Mucinous Neoplasm of the Pancreas in Young Patients: Tumor Biology, Clinical Features, and Survival Outcomes. *Journal of Gastrointestinal Surgery*, **2018**, 22, 226-234	3.3	8
426	Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers. *Advances in Radiation Oncology*, **2018**, 3, 42-51	3.3	1
425	Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2018**, 100, 486-489	4	0
424	New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. *Advances in Anatomic Pathology*, **2018**, 25, 131-142	5.1	30
423	The Evolution of Earned, Transparent, and Quantifiable Faculty Salary Compensation: The Johns Hopkins Pathology Experience. *Academic Pathology*, **2018**, 5, 2374289518777463	1.3	5
422	Incidentally detected pancreatic neuroendocrine microadenoma with lymph node metastasis. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2018**, 473, 649-653	5.1	7
421	Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. *Annals of Surgical Oncology*, **2018**, 25, 2475-2483	3.1	46
420	The Johns Hopkins Department of Pathology Novel Organizational Model: A 25-Year-Old Ongoing Experiment. *Academic Pathology*, **2018**, 5, 2374289518811145	1.3	3
419	Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. *Annals of Surgery*, **2018**, 267, 936-945	7.8	215
418	Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid. *Journal of Molecular Diagnostics*, **2018**, 20, 46-55	5.1	8

417	Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype. *Cancer*, **2018**, 124, 636-647	6.4	7
416	Cancerization of the Pancreatic Ducts: Demonstration of a Common and Under-recognized Process Using Immunolabeling of Paired Duct Lesions and Invasive Pancreatic Ductal Adenocarcinoma for p53 and Smad4 Expression. *American Journal of Surgical Pathology*, **2018**, 42, 1556-1561	6.7	18
415	Genomic analysis identifies frequent deletions of Dystrophin in olfactory neuroblastoma. *Nature Communications*, **2018**, 9, 5410	17.4	14
414	Clinical and Radiographic Gastrointestinal Abnormalities in McCune-Albright Syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 4293-4303	5.6	12
413	Precancerous neoplastic cells can move through the pancreatic ductal system. *Nature*, **2018**, 561, 201-205	50.4	55
412	Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. *Modern Pathology*, **2018**, 31, 1532-1538	9.8	15
411	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. *Cancer Discovery*, **2018**, 8, 1112-1129	24.4	394
410	Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. *Gastroenterology*, **2018**, 155, 740-751.e2	13.3	154
409	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. *ELife*, **2018**, 7,	8.9	72
408	A novel approach for selecting combination clinical markers of pathology applied to a large retrospective cohort of surgically resected pancreatic cysts. *Journal of the American Medical Informatics Association: JAMIA*, **2017**, 24, 145-152	8.6	24
407	Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma. *Annals of Surgery*, **2017**, 265, 185-191	7.8	277
406	Predicting the Grade of Dysplasia of Pancreatic Cystic Neoplasms Using Cyst Fluid DNA Methylation Markers. *Clinical Cancer Research*, **2017**, 23, 3935-3944	12.9	40
405	Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. *Nature Genetics*, **2017**, 49, 358-366	36.3	228
404	Reconstituting development of pancreatic intraepithelial neoplasia from primary human pancreas duct cells. *Nature Communications*, **2017**, 8, 14686	17.4	32
403	Alterations of type II classical cadherin, cadherin-10 (CDH10), is associated with pancreatic ductal adenocarcinomas. *Genes Chromosomes and Cancer*, **2017**, 56, 427-435	5	6
402	Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms. *Gut*, **2017**, 66, 1677-1687	19.2	104
401	Abdominal schwannomas: review of imaging findings and pathology. *Abdominal Radiology*, **2017**, 42, 1864-1870	3	24
400	Patients with McCune-Albright syndrome have a broad spectrum of abnormalities in the gastrointestinal tract and pancreas. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2017**, 470, 391-400	5.1	33

399	Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4. *Journal of Pathology*, **2017**, 242, 16-23	9.4	71
398	Patients with a resected pancreatic mucinous cystic neoplasm have a better prognosis than patients with an intraductal papillary mucinous neoplasm: A large single institution series. *Pancreatology*, **2017**, 17, 490-496	3.8	14
397	Duodenal Involvement is an Independent Prognostic Factor for Patients with Surgically Resected Pancreatic Ductal Adenocarcinoma. *Annals of Surgical Oncology*, **2017**, 24, 2379-2386	3.1	8
396	Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. *Annals of Surgery*, **2017**, 266, 133-141	7.8	79
395	Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. *Cancer Cytopathology*, **2017**, 125, 544-551	3.9	29
394	A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. *Cancer Cell*, **2017**, 32, 460-473.e6	24.3	93
393	Classification of Pancreatic Cysts in Computed Tomography Images Using a Random Forest and Convolutional Neural Network Ensemble. *Lecture Notes in Computer Science*, **2017**, 10435, 150-158	0.9	25
392	IL2RG, identified as overexpressed by RNA-seq profiling of pancreatic intraepithelial neoplasia, mediates pancreatic cancer growth. *Oncotarget*, **2017**, 8, 83370-83383	3.3	7
391	Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. *Journal of Clinical Oncology*, **2017**, 35, 3382-3390	2.2	207
390	A Novel Absorbable Radiopaque Hydrogel Spacer to Separate the Head of the Pancreas and Duodenum in Radiation Therapy for Pancreatic Cancer. *International Journal of Radiation Oncology Biology Physics*, **2017**, 99, 1111-1120	4	30
389	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 10202-10207	11.5	303
388	Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. *Cancer Cell*, **2017**, 32, 185-203.e13	24.3	896
387	Classification, Morphology, Molecular Pathogenesis, and Outcome of Premalignant Lesions of the Pancreas. *Archives of Pathology and Laboratory Medicine*, **2017**, 141, 1606-1614	5	18
386	Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. *Cancer Medicine*, **2017**, 6, 1552-1562	4.8	14
385	Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival. *Clinical Cancer Research*, **2017**, 23, 1598-1606	12.9	69
384	Hypermutation In Pancreatic Cancer. *Gastroenterology*, **2017**, 152, 68-74.e2	13.3	130
383	Lack of association between the pancreatitis risk allele CEL-HYB and pancreatic cancer. *Oncotarget*, **2017**, 8, 50824-50831	3.3	8
382	A rare case of esophageal metastasis from pancreatic ductal adenocarcinoma: a case report and literature review. *Oncotarget*, **2017**, 8, 100942-100950	3.3	2

381	Duodenal and Ampullary Carcinoid Tumors: Size Predicts Necessity for Lymphadenectomy. *Journal of Gastrointestinal Surgery*, **2017**, 21, 1262-1269	3.3	33
380	Pancreatic cancer. *Nature Reviews Disease Primers*, **2016**, 2, 16022	51.1	838
379	Surgical and molecular pathology of pancreatic neoplasms. *Diagnostic Pathology*, **2016**, 11, 47	3	74
378	A robust nonlinear tissue-component discrimination method for computational pathology. *Laboratory Investigation*, **2016**, 96, 450-8	5.9	6
377	Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. *Cancer Cell*, **2016**, 29, 229-40	24.3	90
376	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. *Cancer Discovery*, **2016**, 6, 166-75	24.4	206
375	Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS. *Gastroenterology*, **2016**, 150, 218-228.e12	13.3	25
374	Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. *Cell Reports*, **2016**, 14, 907-919	10.6	75
373	Mutational spectrum of intraepithelial neoplasia in pancreatic heterotopia. *Human Pathology*, **2016**, 48, 117-21	3.7	9
372	Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature*, **2016**, 531, 47-52	50.4	1785
371	Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. *Gastroenterology*, **2016**, 150, 931-43	13.3	156
370	Obstructive Sleep Apnea and Pathological Characteristics of Resected Pancreatic Ductal Adenocarcinoma. *PLoS ONE*, **2016**, 11, e0164195	3.7	11
369	Germline mutations in Japanese familial pancreatic cancer patients. *Oncotarget*, **2016**, 7, 74227-74235	3.3	49
368	Pathology and Classification of Cystic Tumors of the Pancreas **2016**, 1-21		
367	Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting. *Annals of Surgery*, **2016**, 263, 162-77	7.8	165
366	Pancreatic surgery for tumors in children and adolescents. *Pediatric Surgery International*, **2016**, 32, 779-88	1.1	19
365	Cyst Fluid Telomerase Activity Predicts the Histologic Grade of Cystic Neoplasms of the Pancreas. *Clinical Cancer Research*, **2016**, 22, 5141-5151	12.9	36
364	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1185-91	4	22

363	Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. *Hpb*, **2016**, 18, 236-46	3.8	54
362	Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2016**, 469, 523-532	5.1	42
361	Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. *Ca-A Cancer Journal for Clinicians*, **2016**, 66, 408-36	220.7	26
360	The genetic classification of pancreatic neoplasia. *Journal of Gastroenterology*, **2015**, 50, 520-32	6.9	4
359	Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature*, **2015**, 518, 495-501	50.4	1579
358	CT Detection of Symptomatic and Asymptomatic Meckel Diverticulum. *American Journal of Roentgenology*, **2015**, 205, 281-91	5.4	24
357	Diagnosis: A step closer to screening for curable pancreatic cancer?. *Nature Reviews Gastroenterology and Hepatology*, **2015**, 12, 431-2	24.2	7
356	A combination of molecular markers and clinical features improve the classification of pancreatic cysts. *Gastroenterology*, **2015**, 149, 1501-10	13.3	286
355	Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. *Nature Communications*, **2015**, 6, 7686	17.4	279
354	Managing pancreatic cysts: less is more?. *Gastroenterology*, **2015**, 148, 688-91	13.3	24
353	Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. *Modern Pathology*, **2015**, 28, 1249-64	9.8	66
352	KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 963-9.e4	6.9	59
351	Incremental value of secretin-enhanced magnetic resonance cholangiopancreatography in detecting ductal communication in a population with high prevalence of small pancreatic cysts. *European Journal of Radiology*, **2015**, 84, 575-80	4.7	17
350	Smoking is not associated with severe dysplasia or invasive carcinoma in resected intraductal papillary mucinous neoplasms. *Journal of Gastrointestinal Surgery*, **2015**, 19, 656-65	3.3	9
349	Genetics of pancreatic neuroendocrine tumors: implications for the clinic. *Expert Review of Gastroenterology and Hepatology*, **2015**, 9, 1407-19	4.2	31
348	Postoperative Omental Infarct After Distal Pancreatectomy: Appearance, Etiology Management, and Review of Literature. *Journal of Gastrointestinal Surgery*, **2015**, 19, 2028-37	3.3	9
347	Retrotransposon insertions in the clonal evolution of pancreatic ductal adenocarcinoma. *Nature Medicine*, **2015**, 21, 1060-4	50.5	97
346	Widespread somatic L1 retrotransposition occurs early during gastrointestinal cancer evolution. *Genome Research*, **2015**, 25, 1536-45	9.7	92

345	A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. *Nature*, **2015**, 525, 261-4	50.4	326
344	Intraductal papillary mucinous neoplasm in a neonate with congenital hyperinsulinism and a de novo germline SKIL gene mutation. *Pancreatology*, **2015**, 15, 194-6	3.8	5
343	BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. *Genetics in Medicine*, **2015**, 17, 569-77	8.1	175
342	Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. *Head and Neck*, **2015**, 37, 1642-9	4.2	55
341	A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. *American Journal of Surgical Pathology*, **2015**, 39, 1730-41	6.7	423
340	Transflip mutations produce deletions in pancreatic cancer. *Genes Chromosomes and Cancer*, **2015**, 54, 472-481	5	6
339	Neurogenin 3 Expressing Cells in the Human Exocrine Pancreas Have the Capacity for Endocrine Cell Fate. *PLoS ONE*, **2015**, 10, e0133862	3.7	32
338	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *New England Journal of Medicine*, **2015**, 372, 2509-20	59.2	5560
337	A histomorphologic comparison of familial and sporadic pancreatic cancers. *Pancreatology*, **2015**, 15, 387-391	3.8	22
336	RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. *Cell*, **2015**, 161, 1345-60	56.2	134
335	Organoid models of human and mouse ductal pancreatic cancer. *Cell*, **2015**, 160, 324-38	56.2	1072
334	Familial and sporadic pancreatic cancer share the same molecular pathogenesis. *Familial Cancer*, **2015**, 14, 95-103	3	43
333	Pathological and molecular evaluation of pancreatic neoplasms. *Seminars in Oncology*, **2015**, 42, 28-39	5.5	49
332	Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. *Clinical Cancer Research*, **2015**, 21, 1944-50	12.9	62
331	Circulating tumor DNA (ctDNA) as a prognostic marker for recurrence in resected pancreas cancer.. *Journal of Clinical Oncology*, **2015**, 33, 11025-11025	2.2	1
330	Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. *Oncotarget*, **2015**, 6, 36903-10	3.3	45
329	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. *Journal of Gastrointestinal Oncology*, **2015**, 6, 115-25	2.8	14
328	Pancreatic adenocarcinoma pathology: changing "landscape". *Journal of Gastrointestinal Oncology*, **2015**, 6, 358-74	2.8	32

327	Genomic landscapes of pancreatic neoplasia. *Journal of Pathology and Translational Medicine*, **2015**, 49, 13-22	2.9	13
326	Long interspersed element-1 protein expression is a hallmark of many human cancers. *American Journal of Pathology*, **2014**, 184, 1280-6	5.8	158
325	A draft map of the human proteome. *Nature*, **2014**, 509, 575-81	50.4	1520
324	The great mimickers: Castleman disease. *Seminars in Ultrasound, CT and MRI*, **2014**, 35, 263-71	1.7	18
323	Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics. *Molecular and Cellular Proteomics*, **2014**, 13, 2803-11	7.6	43
322	Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. *Cancer Immunology Research*, **2014**, 2, 616-31	12.5	322
321	The tail of neuroendocrine tumors from lung to pancreas: Two rare case reports. *International Journal of Surgery Case Reports*, **2014**, 5, 537-9	0.8	2
320	Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. *Nature Genetics*, **2014**, 46, 1170-2	36.3	186
319	The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia?. *Cancer Research*, **2014**, 74, 3381-9	10.1	162
318	Role of a multidisciplinary clinic in the management of patients with pancreatic cysts: a single-center cohort study. *Annals of Surgical Oncology*, **2014**, 21, 3668-3674	3.1	37
317	2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. *Hpb*, **2014**, 16, 83-90	3.8	176
316	Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases. *Journal of the American College of Surgeons*, **2014**, 218, 628-35	4.4	27
315	Dual-phase CT findings of groove pancreatitis. *European Journal of Radiology*, **2014**, 83, 1337-43	4.7	23
314	Liver transplant patients have a risk of progression similar to that of sporadic patients with branch duct intraductal papillary mucinous neoplasms. *Liver Transplantation*, **2014**, 20, 1462-7	4.5	5
313	Detection of circulating tumor DNA in early- and late-stage human malignancies. *Science Translational Medicine*, **2014**, 6, 224ra24	17.5	2741
312	Pancreatic Cancer Database: an integrative resource for pancreatic cancer. *Cancer Biology and Therapy*, **2014**, 15, 963-7	4.6	37
311	Overexpression of lymphoid enhancer-binding factor 1 (LEF1) in solid-pseudopapillary neoplasms of the pancreas. *Modern Pathology*, **2014**, 27, 1355-63	9.8	48
310	Adenocarcinoma of the pancreas. *Seminars in Diagnostic Pathology*, **2014**, 31, 443-451	4.3	32

309	Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. *Genes Chromosomes and Cancer*, **2014**, 53, 15-24	5	82
308	Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. *Journal of Pathology*, **2014**, 233, 217-27	9.4	240
307	Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. *Journal of Pathology* , **2014**, 232, 428-35	9.4	118
306	GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs". *American Journal of Surgical Pathology*, **2014**, 38, 360-3	6.7	37
305	A systematic review of solid-pseudopapillary neoplasms: are these rare lesions?. *Pancreas*, **2014**, 43, 331-7	2.6	206
304	Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: The Papanicolaou Society of Cytopathology Guidelines. *CytoJournal*, **2014**, 11, 4	1.1	25
303	Prognostic factors after pancreaticoduodenectomy for duodenal adenocarcinoma: Results from a dual center analysis.. *Journal of Clinical Oncology*, **2014**, 32, e15181-e15181	2.2	
302	Association of recurrence patterns following resection of pancreatic adenocarcinoma with overall survival.. *Journal of Clinical Oncology*, **2014**, 32, 4127-4127	2.2	
301	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.. *Journal of Clinical Oncology*, **2014**, 32, 269-269	2.2	
300	Pancreatic neuroendocrine tumor with cystlike changes: evaluation with MDCT. *American Journal of Roentgenology*, **2013**, 200, W283-90	5.4	55
299	Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012. *Journal of Hepato-Biliary-Pancreatic Sciences*, **2013**, 20, 557-66	2.8	11
298	Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas. *Annals of Surgical Oncology*, **2013**, 20, 3802-8	3.1	127
297	Sclerosing angiomatoid nodular transformation of the spleen (SANT): multimodality imaging appearance of five cases with radiology-pathology correlation. *Abdominal Imaging*, **2013**, 38, 827-34		25
296	Hepatic adenomatosis: spectrum of imaging findings. *Abdominal Imaging*, **2013**, 38, 474-81		7
295	Acinar cell carcinoma of the pancreas: computed tomography features--a study of 15 patients. *Abdominal Imaging*, **2013**, 38, 137-43		36
294	Histopathologic findings of multifocal pancreatic intraductal papillary mucinous neoplasms on CT. *American Journal of Roentgenology*, **2013**, 200, 563-9	5.4	24
293	International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. *Gut*, **2013**, 62, 339-47	19.2	503
292	Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships. *Journal of Radiation Oncology*, **2013**, 2, 413-425	0.7	57

291	The diagnosis and surgical treatment of pancreatoblastoma in adults: a case series and review of the literature. *Journal of Gastrointestinal Surgery*, **2013**, 17, 2153-61	3.3	37
290	Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. *Clinical Gastroenterology and Hepatology*, **2013**, 11, 719-30.e5	6.9	127
289	Young patients undergoing resection of pancreatic cancer fare better than their older counterparts. *Journal of Gastrointestinal Surgery*, **2013**, 17, 339-44	3.3	38
288	Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm?. *Journal of the American College of Surgeons*, **2013**, 216, 657-65; discussion 665-7	4.4	111
287	Personalized chemotherapy profiling using cancer cell lines from selectable mice. *Clinical Cancer Research*, **2013**, 19, 1139-46	12.9	21
286	Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. *American Journal of Surgical Pathology*, **2013**, 37, 1671-7	6.7	123
285	Recent progress in pancreatic cancer. *Ca-A Cancer Journal for Clinicians*, **2013**, 63, 318-48	220.7	606
284	Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. *Gut*, **2013**, 62, 1024-33	19.2	135
283	Molecular Pathology of Pancreatic Cancer **2013**, 17-42		4
282	Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer. *Pancreas*, **2013**, 42, 160-7	2.6	20
281	First report of the correlation of PET Response Criteria in Solid Tumors (PERCIST) criteria and pathologic change in patients with rectal cancer treated with neoadjuvant radiation.. *Journal of Clinical Oncology*, **2013**, 31, 261-261	2.2	1
280	Phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy for resectable pancreatic cancer.. *Journal of Clinical Oncology*, **2013**, 31, 269-269	2.2	
279	Prognostic factors for achieving resection following neoadjuvant radiation therapy for borderline resectable pancreatic adenocarcinoma.. *Journal of Clinical Oncology*, **2013**, 31, 285-285	2.2	
278	Duodenal and ampullary carcinoid tumors: Using size to predict necessity for lymphadenectomy.. *Journal of Clinical Oncology*, **2013**, 31, 316-316	2.2	
277	Hemoglobin-A1c level to predict for clinical outcomes in patients with pancreatic cancer.. *Journal of Clinical Oncology*, **2013**, 31, 4039-4039	2.2	
276	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.. *Journal of Clinical Oncology*, **2013**, 31, e15028-e15028	2.2	
275	Is successful resection following neoadjuvant radiation therapy for borderline resectable pancreatic cancer dependent on improved tumor-vessel relationships?. *Journal of Clinical Oncology*, **2013**, 31, 4057-4057	2.2	
274	Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. *Human Mutation*, **2012**, 33, 100-3	4.7	230

273	Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: implications for radiation therapy planning. *Radiotherapy and Oncology*, **2012**, 104, 167-72	5.3	20
272	GNAS codon 201 mutations are uncommon in intraductal papillary neoplasms of the bile duct. *Hpb*, **2012**, 14, 677-83	3.8	36
271	MicroRNA alterations of pancreatic intraepithelial neoplasias. *Clinical Cancer Research*, **2012**, 18, 981-92	12.9	181
270	Intraductal papillary mucinous neoplasm. *Human Pathology*, **2012**, 43, 1-16	3.7	90
269	Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas. *Human Pathology*, **2012**, 43, 585-91	3.7	48
268	Serotonin expression in pancreatic neuroendocrine tumors correlates with a trabecular histologic pattern and large duct involvement. *Human Pathology*, **2012**, 43, 1169-76	3.7	50
267	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature*, **2012**, 491, 399-405	36.4	1427
266	Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. *Nature Reviews Gastroenterology and Hepatology*, **2012**, 9, 199-208	24.2	88
265	Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. *Gastroenterology*, **2012**, 142, 730-733.e9	13.3	451
264	Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. *Gastroenterology*, **2012**, 142, 796-804; quiz e14-5	13.3	455
263	Reporting precursors to invasive pancreatic cancer: pancreatic intraepithelial neoplasia, intraductal neoplasms and mucinous cystic neoplasm. *Diagnostic Histopathology*, **2012**, 18, 17-30	0.7	16
262	Rosai-dorfman disease (sinus histiocytosis with massive lymphadenopathy) of the pancreas: third reported occurrence. *Journal of Gastrointestinal Cancer*, **2012**, 43, 626-9	1.6	15
261	Pancreatic imaging mimics: part 2, pancreatic neuroendocrine tumors and their mimics. *American Journal of Roentgenology*, **2012**, 199, 309-18	5.4	80
260	Beyond renal cell carcinoma: rare and unusual renal masses. *Abdominal Radiology*, **2012**, 37, 873-84	3	36
259	A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys. *PLoS ONE*, **2012**, 7, e39036	3.7	48
258	Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. *Clinical Cancer Research*, **2012**, 18, 6519-30	12.9	51
257	ATM mutations in patients with hereditary pancreatic cancer. *Cancer Discovery*, **2012**, 2, 41-6	24.4	365
256	Genome-wide CpG island profiling of intraductal papillary mucinous neoplasms of the pancreas. *Clinical Cancer Research*, **2012**, 18, 700-12	12.9	53

255	miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. *Clinical Cancer Research*, **2012**, 18, 4713-24	12.9	127
254	Pathology and molecular genetics of pancreatic neoplasms. *Cancer Journal (Sudbury, Mass)*, **2012**, 18, 492-501	2.2	88
253	Human correlates of provocative questions in pancreatic pathology. *Advances in Anatomic Pathology*, **2012**, 19, 351-62	5.1	23
252	Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer. *Clinical Cancer Research*, **2012**, 18, 4303-12	12.9	36
251	Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. *Modern Pathology*, **2012**, 25, 1033-9	9.8	134
250	Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. *Clinical Cancer Research*, **2012**, 18, 4257-65	12.9	101
249	Vascular invasion in infiltrating ductal adenocarcinoma of the pancreas can mimic pancreatic intraepithelial neoplasia: a histopathologic study of 209 cases. *American Journal of Surgical Pathology*, **2012**, 36, 235-41	6.7	30
248	Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. *Annals of Surgery*, **2012**, 255, 326-33	7.8	99
247	Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. *American Journal of Surgical Pathology*, **2012**, 36, 173-84	6.7	366
246	Non-neoplastic and neoplastic pathology of the pancreas **2012**, 514-556		0
245	Patient retention and costs associated with a pancreatic multidisciplinary clinic.. *Journal of Clinical Oncology*, **2012**, 30, 96-96	2.2	
244	Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. *Pancreatology*, **2011**, 11, 343-50	3.8	88
243	Pancreatic Intraepithelial Neoplasia. *Surgical Pathology Clinics*, **2011**, 4, 523-35	3.9	8
242	Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. *Nature*, **2011**, 475, 106-9	50.4	1458
241	Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. *Annals of Surgical Oncology*, **2011**, 18, 3493-9	3.1	44
240	DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. *Science*, **2011**, 331, 1199-203	33.3	1252
239	Pancreatic cancer. *Lancet, The*, **2011**, 378, 607-20	40	1693
238	A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. *Annals of Surgery*, **2011**, 253, 328-35	7.8	301

237	Hyaline globules in neuroendocrine and solid-pseudopapillary neoplasms of the pancreas: a clue to the diagnosis. *American Journal of Surgical Pathology*, **2011**, 35, 981-8	6.7	43
236	Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. *Indian Journal of Surgical Oncology*, **2011**, 2, 9-15	0.7	2
235	Telomeres are shortened in acinar-to-ductal metaplasia lesions associated with pancreatic intraepithelial neoplasia but not in isolated acinar-to-ductal metaplasias. *Modern Pathology*, **2011**, 24, 256-66	9.8	30
234	Small serotonin-producing neuroendocrine tumor of the pancreas associated with pancreatic duct obstruction. *American Journal of Roentgenology*, **2011**, 197, W482-8	5.4	46
233	Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. *Modern Pathology*, **2011**, 24, 1237-47	9.8	74
232	Altered telomeres in tumors with ATRX and DAXX mutations. *Science*, **2011**, 333, 425	33.3	717
231	Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. *Science Translational Medicine*, **2011**, 3, 92ra66	17.5	599
230	Cystic precursors to invasive pancreatic cancer. *Nature Reviews Gastroenterology and Hepatology*, **2011**, 8, 141-50	24.2	129
229	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 21188-93	11.5	484
228	Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. *Molecular Cancer Therapeutics*, **2011**, 10, 3-8	6.1	208
227	FAM190A rearrangements provide a multitude of individualized tumor signatures and neo-antigens in cancer. *Oncotarget*, **2011**, 2, 69-75	3.3	9
226	Molecular characteristics of pancreatic ductal adenocarcinoma. *Pathology Research International*, **2011**, 2011, 620601		33
225	Molecular signatures of pancreatic cancer. *Archives of Pathology and Laboratory Medicine*, **2011**, 135, 716-27	5	116
224	In vivo and in vitro propagation of intraductal papillary mucinous neoplasms. *Laboratory Investigation*, **2010**, 90, 665-73	5.9	11
223	Distant metastasis occurs late during the genetic evolution of pancreatic cancer. *Nature*, **2010**, 467, 1114-7	36.4	1834
222	Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. *Cancer Prevention Research*, **2010**, 3, 1427-34	3.2	72
221	Pancreatic duct stenosis secondary to small endocrine neoplasms: a manifestation of serotonin production?. *Radiology*, **2010**, 257, 107-14	20.5	46
220	Mixed epithelial and stromal tumor of the kidney: radiologic-pathologic correlation. *Radiographics*, **2010**, 30, 1541-51	5.4	42

219	Update on familial pancreatic cancer. *Advances in Surgery*, **2010**, 44, 293-311	1.2	177
218	Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. *Pancreatology*, **2010**, 10, 66-73	3.8	102
217	Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients. *Human Pathology*, **2010**, 41, 113-22	3.7	61
216	Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. *Annals of Surgery*, **2010**, 251, 470-6	7.8	171
215	Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, 839-44	4	46
214	The Pancreas **2010**, 891-904		3
213	Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science*, **2009**, 324, 1457-61	33.3	2364
212	Absence of deleterious palladin mutations in patients with familial pancreatic cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 1328-30	4	31
211	DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. *Journal of Clinical Oncology*, **2009**, 27, 1806-13	2.2	793
210	Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science*, **2009**, 324, 217	33.3	608
209	A compendium of potential biomarkers of pancreatic cancer. *PLoS Medicine*, **2009**, 6, e1000046	11.6	217
208	Elevated cancer mortality in the relatives of patients with pancreatic cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 2829-34	4	51
207	Absence of germline BRCA1 mutations in familial pancreatic cancer patients. *Cancer Biology and Therapy*, **2009**, 8, 131-5	4.6	40
206	Adult pancreatic hemangioma: case report and literature review. *Gastroenterology Research and Practice*, **2009**, 2009, 839730	2	27
205	SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. *Clinical Cancer Research*, **2009**, 15, 4674-9	12.9	275
204	Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. *Clinical Cancer Research*, **2009**, 15, 7737-7743	12.9	172
203	KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. *Molecular Cancer Research*, **2009**, 7, 230-6	6.6	83
202	Surgical management of solid-pseudopapillary neoplasms of the pancreas (Franz or Hamoudi tumors): a large single-institutional series. *Journal of the American College of Surgeons*, **2009**, 208, 950-7; discussion 957-9	4.4	177

201	Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia. *Modern Pathology*, **2009**, 22, 1439-45	9.8	34
200	Molecular classification of neoplasms of the pancreas. *Human Pathology*, **2009**, 40, 612-23	3.7	73
199	Loss of the acinar-restricted transcription factor Mist1 accelerates Kras-induced pancreatic intraepithelial neoplasia. *Gastroenterology*, **2009**, 136, 1368-78	13.3	120
198	Pancreatic cancer. Special issue--insights and controversies in pancreatic pathology. *Archives of Pathology and Laboratory Medicine*, **2009**, 133, 347-9	5	7
197	Familial pancreatic cancer. *Archives of Pathology and Laboratory Medicine*, **2009**, 133, 365-74	5	131
196	An algorithmic approach to the diagnosis of pancreatic neoplasms. *Archives of Pathology and Laboratory Medicine*, **2009**, 133, 454-64	5	65
195	Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. *Modern Pathology*, **2008**, 21, 1499-507	9.8	68
194	CpG island methylation profile of pancreatic intraepithelial neoplasia. *Modern Pathology*, **2008**, 21, 238-44	9.8	99
193	Pancreatic cancer. *Annual Review of Pathology: Mechanisms of Disease*, **2008**, 3, 157-88	34	541
192	Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas. *Gastroenterology*, **2008**, 134, 2080-90	13.3	114
191	The foamy variant of pancreatic intraepithelial neoplasia. *Annals of Diagnostic Pathology*, **2008**, 12, 252-259	2.2	14
190	Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science*, **2008**, 321, 1801-6	33.3	3223
189	Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. *Cancer Biology and Therapy*, **2008**, 7, 353-360	4.6	60
188	Allele-specific expression in the germline of patients with familial pancreatic cancer: an unbiased approach to cancer gene discovery. *Cancer Biology and Therapy*, **2008**, 7, 135-44	4.6	37
187	Genetic and epigenetic alterations of familial pancreatic cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 3536-42	4	72
186	Is surgery required for patients with intraductal papillary mucinous neoplasms without mural nodules?. *Nature Reviews Gastroenterology & Hepatology*, **2008**, 5, 598-9		2
185	Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. *Clinical Cancer Research*, **2008**, 14, 412-8	12.9	129
184	Prevalence of unsuspected pancreatic cysts on MDCT. *American Journal of Roentgenology*, **2008**, 191, 802-7	5.4	636

183	New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. *American Journal of Surgical Pathology*, **2008**, 32, 188-96	6.7	100
182	Undifferentiated carcinoma with osteoclastic giant cells (UCOCGC) of the pancreas associated with the familial atypical multiple mole melanoma syndrome (FAMMM). *American Journal of Surgical Pathology*, **2008**, 32, 1905-9	6.7	19
181	Molecular characterization of pancreatic neoplasms. *Advances in Anatomic Pathology*, **2008**, 15, 185-95	5.1	34
180	Cystic lesions of the pancreas. *Diagnostic Histopathology*, **2008**, 14, 260-265	0.7	5
179	Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. *Annals of Surgical Oncology*, **2008**, 15, 2081-8	3.1	179
178	Update on pancreatic intraepithelial neoplasia. *International Journal of Clinical and Experimental Pathology*, **2008**, 1, 306-16	1.4	144
177	Emerging molecular biology of pancreatic cancer. *Gastrointestinal Cancer Research: GCR*, **2008**, 2, S10-5		13
176	Pancreatic Intraepithelial Neoplasia **2008**, 41-51		2
175	Precursors to pancreatic cancer. *Gastroenterology Clinics of North America*, **2007**, 36, 831-49, vi	4.4	140
174	Pancreatic adenocarcinoma: update on the surgical pathology of carcinomas of ductal origin and PanINs. *Modern Pathology*, **2007**, 20 Suppl 1, S61-70	9.8	79
173	Chromosomal abnormalities of adenocarcinoma of the pancreas: identifying early and late changes. *Cancer Genetics and Cytogenetics*, **2007**, 178, 26-35		33
172	Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. *Cancer Cell*, **2007**, 11, 229-43	24.3	289
171	Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. *Surgery*, **2007**, 141, 610-8	3.6	352
170	Molecular genetics of pancreatic intraepithelial neoplasia. *Journal of Hepato-Biliary-Pancreatic Surgery*, **2007**, 14, 224-32		171
169	Clinical importance of precursor lesions in the pancreas. *Journal of Hepato-Biliary-Pancreatic Surgery*, **2007**, 14, 255-63		56
168	Resected serous cystic neoplasms of the pancreas: a review of 158 patients with recommendations for treatment. *Journal of Gastrointestinal Surgery*, **2007**, 11, 820-6	3.3	158
167	The prevalence of BRCA2 mutations in familial pancreatic cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 342-6	4	217
166	Copy-number variants in patients with a strong family history of pancreatic cancer. *Cancer Biology and Therapy*, **2007**, 6, 1592-9	4.6	33

165	Palladin is overexpressed in the non-neoplastic stroma of infiltrating ductal adenocarcinomas of the pancreas, but is only rarely overexpressed in neoplastic cells. *Cancer Biology and Therapy*, **2007**, 6, 324-8	4.6	47
164	PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. *Clinical Cancer Research*, **2007**, 13, 7380-7	12.9	73
163	Advances in counselling and surveillance of patients at risk for pancreatic cancer. *Gut*, **2007**, 56, 1460-9	19.2	215
162	PancPRO: risk assessment for individuals with a family history of pancreatic cancer. *Journal of Clinical Oncology*, **2007**, 25, 1417-22	2.2	150
161	Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. *Clinical Cancer Research*, **2007**, 13, 2870-5	12.9	279
160	Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. *American Journal of Pathology*, **2007**, 171, 263-73	5.8	165
159	Familial pancreatic cancer: from genes to improved patient care. *Expert Review of Gastroenterology and Hepatology*, **2007**, 1, 81-8	4.2	14
158	Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: initial imaging in experimental models of pancreatic cancer. *Molecular Imaging*, **2007**, 6, 131-9	3.7	24
157	Molecular pathogenesis of pancreatic cancer. *Baillière's Best Practice and Research in Clinical Gastroenterology*, **2006**, 20, 211-26	2.5	135
156	1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. *Journal of Gastrointestinal Surgery*, **2006**, 10, 1199-210; discussion 1210-1	3.3	1132
155	Precancer: a conceptual working definition -- results of a Consensus Conference. *Cancer Detection and Prevention*, **2006**, 30, 387-94		60
154	Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. *Surgery*, **2006**, 140, 764-72	3.6	184
153	MDCT of intraductal papillary mucinous neoplasm of the pancreas: evaluation of features predictive of invasive carcinoma. *American Journal of Roentgenology*, **2006**, 186, 687-95	5.4	120
152	Multi-detector row CT of pancreatic islet cell tumors. *Radiographics*, **2006**, 26, 453-64	5.4	118
151	Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. *Cancer Research*, **2006**, 66, 95-106	10.1	357
150	DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. *Cancer Research*, **2006**, 66, 1208-17	10.1	181
149	Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. *Cancer Research*, **2006**, 66, 7920-8	10.1	74
148	Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. *Cancer Research*, **2006**, 66, 242-7	10.1	116

147	Pancreatic cancer genetic epidemiology consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 704-10	4	116
146	Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. *Molecular and Cellular Proteomics*, **2006**, 5, 157-71	7.6	372
145	Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. *Clinical Gastroenterology and Hepatology*, **2006**, 4, 766-81; quiz 665	6.9	402
144	Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. *American Journal of Surgical Pathology*, **2006**, 30, 1067-76	6.7	222
143	Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. *Cancer Biology and Therapy*, **2005**, 4, 83-6	4.6	59
142	Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype. *Cancer Biology and Therapy*, **2005**, 4, 302-7	4.6	31
141	Intestinal and oncocytic variants of pancreatic intraepithelial neoplasia. A morphological and immunohistochemical study. *Annals of Diagnostic Pathology*, **2005**, 9, 69-76	2.2	19
140	Identification and analysis of precursors to invasive pancreatic cancer. *Methods in Molecular Medicine*, **2005**, 103, 1-13		31
139	Precursors to invasive pancreatic cancer. *Advances in Anatomic Pathology*, **2005**, 12, 81-91	5.1	228
138	Histopathological diagnosis of pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms: interobserver agreement. *Pancreas*, **2005**, 31, 344-9	2.6	78
137	Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways. *Modern Pathology*, **2005**, 18, 752-61	9.8	79
136	Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. *Modern Pathology*, **2005**, 18, 959-63	9.8	87
135	Genome-wide aberrations in pancreatic adenocarcinoma. *Cancer Genetics and Cytogenetics*, **2005**, 161, 36-50		95
134	Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. *Cancer Cell*, **2005**, 7, 469-83	24.3	1684
133	Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2005**, 447, 794-9	5.1	517
132	Treatment of familial pancreatic cancer and its precursors. *Current Treatment Options in Gastroenterology*, **2005**, 8, 365-75	2.5	11
131	Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. *Cancer Research*, **2005**, 65, 1619-26	10.1	199
130	In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. *Clinical Cancer Research*, **2005**, 11, 7508-15	12.9	137

129	Intraductal papillary mucinous neoplasm of the pancreas: can benign lesions be differentiated from malignant lesions with multidetector CT?. *Radiographics*, **2005**, 25, 1451-68; discussion 1468-70	5.4	77
128	Lymphoplasmacytic sclerosing pancreatitis with obstructive jaundice: CT and pathology features. *American Journal of Roentgenology*, **2004**, 183, 915-21	5.4	36
127	The genetics of FANCC and FANCG in familial pancreatic cancer. *Cancer Biology and Therapy*, **2004**, 3, 167-9	4.6	66
126	Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. *Cancer Research*, **2004**, 64, 871-5	10.1	66
125	Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. *Cancer Research*, **2004**, 64, 2634-8	10.1	473
124	Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. *Journal of Experimental Medicine*, **2004**, 200, 297-306	16.6	278
123	Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. *Clinical Cancer Research*, **2004**, 10, 2386-92	12.9	221
122	Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. *Cancer Biology and Therapy*, **2004**, 3, 1254-61	4.6	66
121	LigAmp for sensitive detection of single-nucleotide differences. *Nature Methods*, **2004**, 1, 141-7	21.6	317
120	Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. *Clinical Gastroenterology and Hepatology*, **2004**, 2, 606-21	6.9	353
119	Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. *American Journal of Pathology*, **2004**, 164, 903-14	5.8	176
118	Functional defects in the fanconi anemia pathway in pancreatic cancer cells. *American Journal of Pathology*, **2004**, 165, 651-7	5.8	106
117	Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. *Human Pathology*, **2004**, 35, 357-66	3.7	121
116	Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. *Annals of Surgery*, **2004**, 239, 788-97; discussion 797-9	7.8	659
115	Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors. *Clinical Cancer Research*, **2004**, 10, 1597-604	12.9	82
114	An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. *American Journal of Surgical Pathology*, **2004**, 28, 977-87	6.7	836
113	Identification of novel highly expressed genes in pancreatic ductal adenocarcinomas through a bioinformatics analysis of expressed sequence tags. *Cancer Biology and Therapy*, **2004**, 3, 1081-9; discussion 1090-1	4.6	45
112	Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas. *American Journal of Surgical Pathology*, **2004**, 28, 839-48	6.7	384

111	Pancreatic intraepithelial neoplasia. *Pancreas*, **2004**, 28, 257-62	2.6	58
110	Frequent HIN-1 Promoter Methylation and Lack of Expression in Multiple Human Tumor Types. *Molecular Cancer Research*, **2004**, 2, 489-494	6.6	33
109	Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice. *Cancer Biology and Therapy*, **2003**, 2, 78-83	4.6	91
108	Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all chronic pancreatitis?. *American Journal of Surgical Pathology*, **2003**, 27, 110-20	6.7	280
107	Gene expression in neoplasms of the pancreas: applications to diagnostic pathology. *Advances in Anatomic Pathology*, **2003**, 10, 125-34	5.1	10
106	Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs: Coupling of gel-forming mucin (MUC2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas. *American Journal of Surgical Pathology*, **2003**, 27, 571-8	6.7	148
105	p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis. *American Journal of Surgical Pathology*, **2003**, 27, 1495-501	6.7	93
104	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell*, **2003**, 4, 437-50	24.3	1772
103	Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. *Modern Pathology*, **2003**, 16, 686-91	9.8	94
102	Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. *Modern Pathology*, **2003**, 16, 902-12	9.8	317
101	BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. *American Journal of Pathology*, **2003**, 163, 1255-60	5.8	198
100	Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. *American Journal of Pathology*, **2003**, 162, 1151-62	5.8	397
99	Familial pancreatic cancer: where are we in 2003?. *Journal of the National Cancer Institute*, **2003**, 95, 180-1	9.7	40
98	Surgical Pathology Dissection **2003**,		30
97	Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. *Cancer Research*, **2003**, 63, 994-9	10.1	90
96	Fanconi anemia gene mutations in young-onset pancreatic cancer. *Cancer Research*, **2003**, 63, 2585-8	10.1	168
95	Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. *Cancer Research*, **2003**, 63, 3735-42	10.1	231
94	Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. *Cancer Research*, **2003**, 63, 8614-22	10.1	299

93	Evidence for a major gene influencing risk of pancreatic cancer. *Genetic Epidemiology*, **2002**, 23, 133-49	2.6	108
92	Pancreatic cancer. *Current Problems in Cancer*, **2002**, 26, 176-275	2.3	221
91	Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47. *American Journal of Clinical Pathology*, **2002**, 118, 52-9	1.9	116
90	MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. *American Journal of Clinical Pathology*, **2002**, 117, 791-6	1.9	199
89	Tissue protection immunohistochemistry: a useful adjunct in the interpretation of prostate biopsy specimens and other selected cases in which immunostains are needed on minute lesions. *American Journal of Clinical Pathology*, **2002**, 117, 194-8	1.9	146
88	Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. *Modern Pathology*, **2002**, 15, 441-7	9.8	104
87	An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. *Cancer Biology and Therapy*, **2002**, 1, 607-13	4.6	40
86	Aberrant methylation of the 5NCpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanINs. *Cancer Biology and Therapy*, **2002**, 1, 293-6	4.6	104
85	Almost all infiltrating colloid carcinomas of the pancreas and periampullary region arise from in situ papillary neoplasms: a study of 39 cases. *American Journal of Surgical Pathology*, **2002**, 26, 56-63	6.7	114
84	Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. *Annals of Surgery*, **2002**, 236, 355-66; discussion 366-8	7.8	593
83	Primitive neuroectodermal tumors of the pancreas: a report of seven cases of a rare neoplasm. *American Journal of Surgical Pathology*, **2002**, 26, 1040-7	6.7	70
82	Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. *American Journal of Pathology*, **2002**, 160, 1573-81	5.8	176
81	Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. *American Journal of Pathology*, **2002**, 160, 1239-49	5.8	252
80	Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. *American Journal of Pathology*, **2002**, 160, 1361-9	5.8	378
79	Beckwith-Wiedemann syndrome, pancreatoblastoma, and the wnt signaling pathway. *American Journal of Pathology*, **2002**, 160, 1541-2; author reply 1542	5.8	29
78	Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. *American Journal of Pathology*, **2002**, 160, 91-9	5.8	148
77	Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. *American Journal of Pathology*, **2002**, 161, 1541-7	5.8	279
76	Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. *American Journal of Pathology*, **2002**, 160, 953-62	5.8	224

75	Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. *Gastroenterology*, **2002**, 123, 365-72	13.3	108
74	The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. *Modern Pathology*, **2002**, 15, 1087-95	9.8	228
73	Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. *Cancer Research*, **2002**, 62, 3789-93	10.1	292
72	Clear cell endocrine pancreatic tumor mimicking renal cell carcinoma: a distinctive neoplasm of von Hippel-Lindau disease. *American Journal of Surgical Pathology*, **2001**, 25, 602-9	6.7	96
71	Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. *Cancer*, **2001**, 91, 1332-1341	6.4	101
70	Prognostic significance of the labeling of Adnab-9 in pancreatic intraductal papillary mucinous neoplasms. *International Journal of Gastrointestinal Cancer*, **2001**, 29, 141-50		10
69	Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. *Circulation*, **2001**, 103, 2289-95	16.7	354
68	Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas : frequent alterations in the APC/beta-catenin pathway and chromosome 11p. *American Journal of Pathology*, **2001**, 159, 1619-27	5.8	211
67	STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. *American Journal of Pathology*, **2001**, 159, 2017-22	5.8	214
66	Loss of heterozygosity or intragenic mutation, which comes first?. *American Journal of Pathology*, **2001**, 158, 1561-3	5.8	17
65	Pancreatic intraepithelial neoplasia and infiltrating adenocarcinoma: analysis of progression and recurrence by DPC4 immunohistochemical labeling. *Human Pathology*, **2001**, 32, 638-42	3.7	33
64	Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. *Journal of Clinical Oncology*, **2001**, 19, 145-56	2.2	485
63	Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. *Annals of Surgery*, **2001**, 234, 313-21; discussion 321-2	7.8	233
62	Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. *American Journal of Surgical Pathology*, **2001**, 25, 579-86	6.7	917
61	Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. *American Journal of Surgical Pathology*, **2000**, 24, 1544-8	6.7	137
60	Genomic FHIT analysis in RER+ and RER adenocarcinomas of the pancreas **2000**, 27, 239-243		14
59	Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. *International Journal of Radiation Oncology Biology Physics*, **2000**, 48, 1089-96	4	39
58	Pancreatic mucinous cystic neoplasms with sarcomatous stroma: molecular evidence for monoclonal origin with subsequent divergence of the epithelial and sarcomatous components. *Modern Pathology*, **2000**, 13, 86-91	9.8	50

57	Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. *American Journal of Pathology*, **2000**, 157, 755-61	5.8	210
56	Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation. *American Journal of Pathology*, **2000**, 156, 37-43	5.8	266
55	Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. *American Journal of Pathology*, **2000**, 156, 1641-51	5.8	225
54	BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. *American Journal of Pathology*, **2000**, 156, 1767-71	5.8	171
53	Genetic progression in the pancreatic ducts. *American Journal of Pathology*, **2000**, 156, 1821-5	5.8	311
52	High-resolution deletion mapping of chromosome arm 1p in pancreatic cancer identifies a major consensus region at 1p35 **1999**, 24, 351-355		15
51	Novel homozygous deletions of chromosomal band 18q22 in pancreatic adenocarcinoma identified by STS marker scanning. *Genes Chromosomes and Cancer*, **1999**, 25, 370-5	5	8
50	Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis **1999**, 26, 185-191		37
49	Large cystic pancreatic neoplasms: pathology, resectability, and outcome. *Annals of Surgical Oncology*, **1999**, 6, 682-90	3.1	33
48	Central nervous system cancers in first-degree relatives and spouses. *Cancer Investigation*, **1999**, 17, 299-308		37
47	Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. *American Journal of Pathology*, **1999**, 154, 1835-40	5.8	326
46	Recommendations for the reporting of pancreatic specimens containing malignant tumors. The Association of Directors of Anatomic and Surgical Pathology. *American Journal of Clinical Pathology*, **1999**, 111, 304-7	1.9	30
45	Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas. *American Journal of Surgical Pathology*, **1999**, 23, 1320-7	6.7	196
44	Molecular genetics and related developments in pancreatic cancer. *Current Opinion in Gastroenterology*, **1999**, 15, 404-9	3	19
43	Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis **1999**, 26, 185		2
42	Fas-mediated apoptosis in accelerated graft arteriosclerosis. *Angiogenesis*, **1998**, 2, 245-54	10.6	10
41	Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area. *International Journal of Cancer*, **1998**, 78, 695-8	7.5	36
40	The Quilty lesion enigma: focal apoptosis/necrosis and lymphocyte subsets in human cardiac allografts. *Pathology International*, **1998**, 48, 191-8	1.8	25

39	K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. *Cancer*, **1998**, 82, 96-103	6.4	80
38	DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. *Journal of Surgical Oncology*, **1998**, 67, 151-9	2.8	96
37	The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. *Journal of Pathology*, **1998**, 186, 247-53	9.4	53
36	Novel germline p16INK4 allele (Asp145Cys) in a family with multiple pancreatic carcinomas. *Human Mutation*, **1998**, 12, 70-70	4.7	40
35	Tumor-suppressor genes in pancreatic cancer. *Journal of Hepato-Biliary-Pancreatic Surgery*, **1998**, 5, 383-91		35
34	PrimaryPneumocystic carinii infection of the small bowel: Presentation as an acute abdomen. *Emergency Radiology*, **1998**, 5, 164-167	3	
33	A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. *Human Gene Therapy*, **1998**, 9, 1951-71	4.8	69
32	Genetics of Pancreatic Cancer. *Surgical Oncology Clinics of North America*, **1998**, 7, 1-23	2.7	141
31	Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. *American Journal of Surgical Pathology*, **1998**, 22, 163-9	6.7	245
30	K-ras oncogene mutations in osteoclast-like giant cell tumors of the pancreas and liver: genetic evidence to support origin from the duct epithelium. *American Journal of Surgical Pathology*, **1998**, 22, 1247-54	6.7	109
29	DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma **1998**, 67, 151		1
28	Gene expression profiles in normal and cancer cells. *Science*, **1997**, 276, 1268-72	33.3	1217
27	Detection of the Human Cytomegalovirus 2.0-kb Immediate Early Gene 1 Transcripts in Permissive and Nonpermissive Infections by RNA in situ Hybridization. *Journal of Biomedical Science*, **1997**, 4, 19-27	13.3	
26	Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. *Human Pathology*, **1996**, 27, 119-24	3.7	170
25	Arterial Delivery of Genetically Labelled Skeletal Myoblasts to the Murine Heart: Long-Term Survival and Phenotypic Modification of Implanted Myoblasts. *Cell Transplantation*, **1996**, 5, 77-91	4	85
24	Tropical pyomyositis: imaging findings and a review of the literature. *Skeletal Radiology*, **1996**, 25, 576-9	2.7	25
23	Pathobiology of cancer of the pancreas. *Journal of Surgical Oncology*, **1995**, 11, 87-96		8
22	Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. *Annals of Surgery*, **1995**, 221, 721-31; discussion 731-3	7.8	724

21	Familial pancreatic cancer and the genetics of pancreatic cancer. *Surgical Clinics of North America*, **1995**, 75, 845-55	4	30
20	Brief report: molecular biology and the early detection of carcinoma of the bladder--the case of Hubert H. Humphrey. *New England Journal of Medicine*, **1994**, 330, 1276-8	59.2	62
19	Case report 854: Eosinophilic granuloma. *Skeletal Radiology*, **1994**, 23, 648-51	2.7	
18	Case report 852. Periosteal osteosarcoma of femur. *Skeletal Radiology*, **1994**, 23, 401-3	2.7	2
17	Case report 854. *Skeletal Radiology*, **1994**, 23, 408-409	2.7	
16	Follicular variant of papillary thyroid carcinoma. A clinicopathologic study. *Cancer*, **1994**, 73, 424-31	6.4	162
15	Chromosome abnormalities in pancreatic adenocarcinoma. *Genes Chromosomes and Cancer*, **1994**, 9, 93-100	3	53
14	Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. *Nature Genetics*, **1994**, 8, 27-32	36.3	980
13	Tumor-associated glycoprotein expression in salivary gland mucoepidermoid carcinomas: an immunohistochemical study using the monoclonal antibody B72.3. *Laryngoscope*, **1994**, 104, 304-8	3.6	7
12	Overexpression of p53 protein in adenocarcinoma of the pancreas. *American Journal of Clinical Pathology*, **1994**, 101, 684-8	1.9	184
11	Ultrastructural evidence of cell-mediated endothelial cell injury in cardiac transplant-related accelerated arteriosclerosis. *Ultrastructural Pathology*, **1993**, 17, 125-36	1.3	18
10	Surgical pathology specimen orientation markers. *Otolaryngology - Head and Neck Surgery*, **1993**, 109, 962-4	5.5	1
9	Endoluminal sealing of vascular wall disruptions with radiofrequency-heated balloon angioplasty. *Catheterization and Cardiovascular Diagnosis*, **1993**, 29, 161-7		5
8	Protection of the internal mammary artery pedicle with polytetrafluoroethylene membrane. *Journal of Cardiac Surgery*, **1993**, 8, 650-5	1.3	20
7	Human papillomavirus in sinonasal papillomas and squamous cell carcinoma. *Laryngoscope*, **1992**, 102, 973-6	3.6	54
6	The glucose transporter and blood-brain barrier of human brain tumors. *Annals of Neurology*, **1990**, 28, 758-65	9.4	60
5	Fine-needle aspiration cytology of monomorphic adenomas. *American Journal of Clinical Pathology*, **1988**, 90, 46-51	1.9	29
4	Acute myelofibrosis. Immunohistochemical study of four cases and comparison with acute megakaryocytic leukemia. *American Journal of Clinical Pathology*, **1987**, 88, 578-88	1.9	36

3	A neoplasm with pancreatic and hepatocellular differentiation presenting with subcutaneous fat necrosis. *American Journal of Clinical Pathology*, **1987**, 88, 639-45	1.9	53
2	In situ characterization of the 3D microanatomy of the pancreas and pancreatic cancer at single cell resolution		13
1	Primary Pancreatic Adenocarcinoma498-542		